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160 Biol Blood Marrow Transplant 18:159-161, 2012M. A. Sekeresidentical results with 75% of all patients receiving
plerixafor with either G-CSF or chemotherapy
plus G-CSF successfully achieving the threshold of
$2  106 CD34/kg. This report recapitulated the
results of Attolica et al. [4] demonstrating that the
yields of CD34/kg after remobilization with plerix-
afor are the best in MM patients (88% success), the
worst in NHL patients (63% success) and, most
importantly, that G-CSF plus plerixafor was at least
as effective at remobilization as G-CSF plus chemo-
therapy plus plerixafor [6].
The report of Attolica et al. [4] confirm and val-
idate the results of many other groups suggesting
that the addition of a small molecule competitive in-
hibitor of CXCR4, plerixafor, provides new hope for
those unfortunate patients with limited marrow re-
serves and who fail initial mobilization and provides
a pathway to autologous stem cell transplantation as
potentially curative therapy for patients with hema-
tologic malignancies. Although this and other re-
ports are consistent and compelling, prospective
randomized trials will be needed to definitively
confirm the role of plerixafor to enhance the mobi-
lization of peripheral blood stem cells in patients
who are undergoing mobilization or remobilization
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Is Better Than Yours
Mikkael A. SekeresGrowing up in Rhode Island, my brother and I
spent hours – I mean, hours – in the schoolyard around
the block from our house arguing over which baseball
team was better: the Yankees or the Red Sox. I rooted
for the Yankees, just like my father and his father, whilemy brother, the second born, favored the Sox. This
was the late 1970s, and we compared player to player
(Jackson vs Rice, Guidry vs Tiant), position to posi-
tion, tirelessly trying to convince the other, based on
the past performance of our teams, which was superior,
and each of us leaving the quarrel convinced the other
was a complete idiot.
Fast forward a few decades, transform the 2 brothers
into hematologic malignancy doctors and the school-
yard into a windowless pathology conference room,
and the same passionate dispute shifts to which acute
myeloid leukemia (AML) cytogenetic risk scheme is
the most predictive of survival. The most widely used
are those from the Medical Research Council of the
United Kingdom (now the National Council Research
Institute), each of the 3 U.S. Cooperative Groups, and
the European Organization for Research and Treat-
ment of Cancer/Gruppo Italiano Malattie Ematolo-
giche Dell’ Adulto [1-5]. They overarchingly share
similar characteristics (everyone agrees corebinding fac-
tors are good, complex cytogenetics are bad, and most
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differ in some of the details. These systems were devel-
oped based largely on patients with de novo AML who
were treated with cytarabine-based induction chemo-
therapy, and thus are limited in their applicability to
other clinical scenarios, including patients treated with
nonintensive or supportive approaches, secondary leu-
kemias, or those undergoing hematopoietic cell tra-
nsplantation (HCT) in first or second complete
remission (CR). Also, as with the baseball argument,
the quality of these cytogenetic ‘‘teams’’ are based on
past performance, with each collaborative group con-
vinced its system is the best, unlikely to be swayed
from that stance by members of another group.
In this issue of BBMT, Armand et al. use data from
the Center for International Blood and Marrow
Transplant Research (CIBMTR) and from the Dana-
Farber Cancer Institute to assess the performance of
these AML cytogenetics classifications schemas in
821 patients with AML who have undergone HCT
in first or second CR, and to validate the Dana-
Farber Cancer Institute schema and a new schema
specifically for patients with AML undergoing HCT,
developed from this multicenter cohort [6]. These
are younger patients (median age 41 years) most of
whom (75%) received myeloablative conditioning
regimens about a decade ago, and approximately half
of whom received a transplant from a matched related
donor. Only 4% had a secondary leukemia due to ther-
apy for another cancer, with patients having AML aris-
ing from an antecedent hematologic disorder such as
myelodysplastic syndromes excluded. Although this
population is similar to those from which the AML cy-
togenetics classifications schemes derive, it may not be
representative of patients with AML referred for trans-
plantation at individual centers. The authors find that
each classification system performs pretty well at pre-
dicting survival after HCT, as measured by area under
the curve fit and prediction error, and no system
appeared statistically better than another at stratifying
patients for overall survival. The CIBMTR system
they derive places – you guessed it – core binding
factors in the good category, complex cytogenetics in
the bad, and most cytogenetic assignments in an inter-
mediate category, although the details do differ from
other schemas, in that patients with a t(8;21) and those
with exactly 3 cytogenetic abnormalities are consid-
ered intermediate risk for overall survival.
So, as a non-transplanting leukemia doctor, how
would I use the CIBMTR schema in deciding which
of my patients to refer for HCT? Hard to say. Right
now, I refer all patients in second CR for transplanta-
tion, regardless of cytogenetics, as it is the only poten-
tially curative option. Moreover, there is something
a bit maudlin about defining risk groups within this
population – their leukemia came back. By definition,
it is a poor risk. Naturally, this decision involvesa balancing of HCT risks, potential benefits, and
patient goals. In first complete remission, I refer all
patients with secondary AML (for the most part, not
included in these analyses), those with core binding
factor abnormalities who have a c-kit mutation
(unknown in these data), those with normal cytogenet-
ics who have FLT3mutations in the absence of NPM1
mutations (also unknown within these data), and those
with poor-risk cytogenetics as defined by most groups,
who presumably would not be declined for HCT
despite having a predicted survival that is worse than
those with CIBMTR favorable or intermediate risk
cytogenetic abnormalities, for even this poor predicted
survival (some) is better than the predicted survival
with chemotherapy alone (almost none) [7,8].
I give the authors a lot of credit for the equipoise
with which they present their data, as in no way do
they propose using it to determine whether or not to
refer a patient to a transplant physician, or instead to
continue with postremission therapy. Rather, for the
time being, this cytogenetics classification system
should be used to help estimate prognosis as patients
decide whether or not to pursue HCT, and in future
risk stratification on clinical trials.
And to argue that the Yankees are the superior
baseball team.
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